Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Astigmatism after toric IOL implantation: a retrospective series of 50 patients from a semi-urban setting in Western India

Poster Details

First Author: R.Baile INDIA

Co Author(s):    P. Rajput   M. Uparkar                 

Abstract Details


To study the impact of Toric IOL implantation on the final spectacle acceptance and astigmatism using a single formula .


The study was conducted in a single referral center teaching institute from Western India in semi-urban population


Pre-operative assessment included , BCVA , IOP, Keratometry with pachymetry , Astigmatism ,Dilated fundus evaluation . Significant retinal pathology or astigmatism was ruled out .Excluded eyes with corneal opacity , Scarring , Pterygium and ocular surface disease . Incision site and IOL positioning was obtained using a Toric Calculator . Incision was marked using Bubble marker .Single surgeon operated all eyes without any complication and a hydrophobic IOL within the bag was implanted in a single sitting.Post-operative IOL positioning and Astigmatism was checked on Day 1,5 and 30 in all eyes .Spectacle acceptance was obtained on Day 30 .


In the 6 month study period 38 patients were operated with Toric IOL implantation . The mean age of patients was 48 (?�) . 28 were Male patients . Bilateral Toric Implantation was done in 14 cases. According to grade of astigmatism pre-operatively the distribution was as follows No of EyesPre-op AstigmatismDay1 Day 5 Day 30Final BCVA Spect Acceptance 15 1-1.50 0.50 0.00 0.00 6/6N8 Plano 10 1.50-2.00 0.50 0.50 0.00 6/6N8 Plano 13 2-2.50 0.75 0.75 0.50 6/9N10 0.5Ds 7 2.6-3.00 1.25 0.75 0.75 6/9N10 0.75 5 3.1-3.5 1.5 1.0 1.0 6/9N10 1.0


The overally excellent results in Refractive outcome in low astigmatism ( < 2.5D) is a definite indication of Implanting Toric IOL . Higher Astigmatism powers ( 3-4D) may need an additional procedure / technique modification to achieve optimum refractive outcomes and compatible patient satisfaction.

Financial Disclosure:


Back to Poster listing